Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132129) titled 'The Role of Inflammatory Cytokines in the Mechanism by Which tDCS Ameliorates Cognitive Impairment Following MECT in Schizophrenia' on Sept. 9.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The Affiliated Kangning Hospital of Ningbo University
Condition:
schizophrenia
Intervention:
Control Group:MECT + tDCS (Sham Stimulation)
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-09-15
Target Sample Size: Control Group:30;Experimental Group:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=341864
P...